Targeted Oncology
A review on various targeted anticancer therapies
Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility?
Advancement in the research on vascular endothelial growth inhibitor (VEGI)
Biosimilar rhG-CSFs: how similar are they?
Biosimilars: Is absence of proof of difference, proof of absence of difference?
Colony stimulating factors (CSF) biosimilars. Progress?
Erythropoietin biosimilars currently available in hematology-oncology
Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
Presently available biosimilars in hematology-oncology: G-CSF
Recent successes of cancer immunotherapy: a new dimension in personalized medicine?
Risk management of biosimilars in oncology: each medicine is a work in progress
Targeting pattern recognition receptors in cancer immunotherapy
Targeting regulatory T cells
The economic pressures for biosimilar drug use in cancer medicine
What do prescribers think of biosimilars?